TCL Archive Cancer Prevention: NSABP Publishes P-1 Data, Finds Risk Of Breast Cancer Cut By 49 Percent September 18, 1998
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
